PEG3350 vs Senna After Urogyn Surgery

Launched by ST. JOSEPH'S HEALTH, NEW YORK · Feb 8, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how effective two different treatments are for relieving constipation after surgery for women's pelvic issues, specifically after urogynecologic surgery. The two treatments being compared are polyethylene glycol 3350 (PEG3350) and senna. Researchers want to find out which treatment helps more women who experience obstructive defecation syndrome (a type of constipation) in the week following their surgery. They will also look into what factors might affect how well these treatments work for patients.

To participate in this trial, women must be at least 18 years old and scheduled for surgery related to pelvic organ prolapse or stress urinary incontinence. However, women who are having other bowel surgeries at the same time or specific device placements will not be eligible. Participants will take the assigned medication daily for a week after surgery, complete a questionnaire about their constipation before and after the surgery, and keep a daily record of their bowel movements. It's important to note that this trial is not yet recruiting participants, but it aims to help improve care for women experiencing constipation post-surgery.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Inclusion criteria includes women scheduled for urogynecologic surgery for pelvic organ prolapse and/or stress urinary incontinence and at least 18 years old.
• Exclusion Criteria:
• • Exclusion criteria include undergoing concomitant bowel surgery (colonic resection, anal sphincter repair, rectovaginal fistula repair, rectopexy) or placement of a sacral neuromodulation device alone.